Elagolix

Brand names: Orilissa · Active ingredient: Elagolix Sodium

In short: ORILISSA is indicated for the management of moderate to severe pain associated with endometriosis. Limitation s of Use: Limit the duration of use based on the dose and coexisting condition .

Forms & strengthsThe 150 mg tablets are light pink, oblong, film-coated tablets with “EL 150” debossed on one side. Each tablet contains 155.2 mg of elagolix sodium equivalent to 150 mg of elagolix. …
LabelAbbVie Inc.
Label updatedAug 31, 2026

What is Elagolix used for?

ORILISSA is indicated for the management of moderate to severe pain associated with endometriosis.

Limitation

s

of Use:

Limit the duration of use based on the dose and coexisting condition .

Elagolix dosage

Exclude pregnancy before starting ORILISSA or start ORILISSA within 7 days from the onset of menses.

Take ORILISSA at approximately the same time each day, with or without food.

Use the lowest effective dose, taking into account the severity of symptoms and treatment objectives [see Warnings and Precautions (

5.1

,

5.3

,

5.4

) and Clinical Studies (

14

)].

Limit the duration of use because of bone loss (Table 1) .

Dosing Regimen | Maximum

Treatment

Duration | Coexisting Condition

Initiate treatment withORILISSA 150 mg once daily | 24 months | None

Consider initiating treatment with ORILISSA 200 mg twice daily | 6 months | Dyspareunia

Initiate treatment with ORILISSA150 mg once daily. Use of 200 mgtwice daily is not recommended. | 6 months | Moderate hepatic impairment (Child-Pugh Class B)

No dosage adjustment of ORILISSA is required in women with mild hepatic impairment (Child-Pugh A).

Compared to women with normal liver function, those with moderate hepatic impairment had approximately 3-fold higher elagolix exposures and those with severe hepatic impairment had approximately 7-fold higher elagolix exposures. Because of these increased exposures and risk for bone loss:

ORILISSA 150 mg once daily is recommended for women with moderate hepatic impairment (Child-Pugh B) with the duration of treatment limited to 6 months. Use of ORILISSA 200 mg twice daily is not recommended for women with moderate hepatic impairment .

ORILISSA is contraindicated in women with severe hepatic impairment (Child-Pugh C) [see Contraindications (

4

), Use in Specific Populations (

8.7

) and Clinical Pharmacology (

12.3

)].

Instruct the patient to take a missed dose of ORILISSA on the same day as soon as she remembers and then resume the regular dosing schedule.

150 mg once daily: take no more than 1 tablet each day.

200 mg twice daily: take no more than 2 tablets each day.

How to take Elagolix — instructions & advice from the label

Advise patients to read the FDA-approved patient labeling (Medication Guide).

Bone Loss

Inform patients about the risk of bone loss. Advise patients that supplementary calcium and vitamin D may be beneficial if dietary intake of calcium and vitamin D is not adequate .

Change in Menstrual Bleeding Pattern, Contraception and Pregnancy

Advise women that ORILISSA may delay the recognition of pregnancy because it may reduce the amount, intensity, or duration of menstrual bleeding. Advise patients to use effective non-hormonal contraception while taking ORILISSA and to discontinue ORILISSA if pregnancy is confirmed .

Suicidal Ideation, Suicidal Behavior, and Exacerbation of Mood Disorders

Advise patients that suicidal ideation and exacerbation of mood disorders may occur with ORILISSA use. Instruct patients to seek immediate medical attention for suicidal ideation and behavior and for new onset or worsening depression, anxiety, or other mood changes .

Liver Injury

Advise patients to promptly seek medical attention in case of signs or symptoms that may reflect liver injury, such as jaundice . …

Warnings & precautions

Do not take this medicine if: ORILISSA is contraindicated in women:

Who are pregnant . Exposure to ORILISSA early in pregnancy may increase the risk of early pregnancy loss.

With known osteoporosis because of the risk of further bone loss

With severe hepatic impairment

Taking inhibitors of organic anion transporting polypeptide (OATP)1B1 (a hepatic uptake transporter) that are known or expected to significantly increase elagolix plasma concentrations

With known hypersensitivity reaction to ORILISSA or any of its inactive components. Reactions have included anaphylaxis and angioedema .

ORILISSA causes a dose-dependent decrease in bone mineral density (BMD). BMD loss is greater with increasing duration of use and may not be completely reversible after stopping treatment . The impact of these BMD decreases on long-term bone health and future fracture risk are unknown.

ORILISSA is contraindicated in women with known osteoporosis . Consider assessment of BMD in patients with a history of a low-trauma fracture or other risk factors for osteoporosis or bone loss. Limit the duration of use to reduce the extent of bone loss . Although the effect of supplementation with calcium and vitamin D was not studied, such supplementation may be beneficial for all patients.

Women who take ORILISSA may experience a reduction in the amount, intensity or duration of menstrual bleeding, which may reduce the ability to recognize the occurrence of a pregnancy in a timely manner . Perform pregnancy testing if pregnancy is suspected, and discontinue ORILISSA if pregnancy is confirmed.

Suicidal ideation and behavior, including one completed suicide, occurred in subjects treated with ORILISSA in the endometriosis clinical trials. …

Elagolix side effects

The following serious adverse reactions are discussed elsewhere in labeling:

Bone loss

Change in menstrual bleeding pattern and reduced ability to recognize pregnancy

Suicidal ideation, suicidal behavior, and exacerbation of mood disorders

Hepatic transaminase elevations

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety of ORILISSA was evaluated in two six-month, randomized, double-blind, placebo-controlled clinical trials [EM-1 (NCT01620528) and EM-2 (NCT01931670)] in which a total of 952 adult women with moderate to severe pain associated with endometriosis were treated with ORILISSA (475 with 150 mg once daily and 477 with 200 mg twice daily) and 734 were treated with placebo. The population age range was 18-49 years old. Women who completed six months of treatment and met eligibility criteria continued treatment in two uncontrolled, blinded six-month extension trials [EM-3 (NCT01760954) and EM-4 (NCT02143713)], for a total treatment duration of up to 12 months.

Serious Adverse Events

Overall, the most common serious adverse events reported for subjects treated with ORILISSA in the two placebo-controlled clinical trials (Studies EM-1 and EM-2) included appendicitis (0.3%), abdominal pain (0.2%), and back pain (0.2%). …

Drug interactions

Elagolix is:

A weak to moderate inducer of cytochrome P450 (CYP) 3A. Co-administration with ORILISSA may decrease plasma concentrations of drugs that are substrates of CYP3A .

A weak inhibitor of CYP 2C19. Co-administration with ORILISSA may increase plasma concentrations of drugs that are substrates of CYP2C19 .

An inhibitor of efflux transporter P-glycoprotein (P-gp). Co-administration with ORILISSA may increase plasma concentrations of drugs that are substrates of P-gp .

The effects of co-administration of ORILISSA on concentrations of concomitant drugs and the clinical recommendations for these drug interactions are summarized in Table 7.

Concomitant

Drug Class:

Drug Name | Effect on Plasma

Exposure of

Concomitant Drug | Clinical Recommendations

Cardiac glycosides: digoxin | ↑ digoxin | Increase monitoring of digoxin concentrations and potential signs and symptoms of clinical toxicity when initiating ORILISSA in patients who are taking digoxin. If ORILISSA is discontinued, increase monitoring of digoxin concentrations.

Benzodiazepines:oral midazolam | ↓ midazolam | Consider increasing the dose of midazolam by no more than 2-fold and individualize midazolam therapy based on the patient’s response. …

About this medicine

ORILISSA (elagolix) tablets for oral administration contain elagolix sodium, the sodium salt of the active moiety elagolix. Elagolix sodium is a nonpeptide small molecule, GnRH receptor antagonist. Elagolix sodium is chemically described as sodium 4-({(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl]-1-phenylethyl}amino)butanoate. Elagolix sodium has a molecular formula of C32H29F5N3O5Na and a molecular weight of 653.58. Elagolix free acid has a molecular weight of 631.60.

Elagolix sodium has the following structural formula:

Elagolix sodium is a white to off white to light yellow powder and is freely soluble in water.

ORILISSA 150 mg tablets are light pink, oblong, film-coated tablets with “EL 150” debossed on one side. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a86757b3-09c5-fd3b-1223-244e94f50a66. Read the full official label on DailyMed.

Related medicines

Gabapentin Meloxicam Acetaminophen and Hydrocodone Duloxetine Prednisone Ibuprofen Tramadol Cyclobenzaprine